ONO PHARMACEUTICAL CO
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
- Conditions
- Multiple System Atrophy (MSA)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 92
- Registration Number
- NCT05923866
- Locations
- 🇺🇸
The Parkinson's Movement and Disorder Institute, Fountain Valley, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL
- Conditions
- Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT05515406
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Northwest Medical Specialities, Tacoma, Washington, United States
🇺🇸Jonsson Comprehensive Cancer Center, Santa Monica, California, United States
A Phase 1 Study of ONO-2020 in Healthy Participants
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 132
- Registration Number
- NCT05507515
- Locations
- 🇺🇸
Altasciences, Cypress, California, United States
Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 33
- Registration Number
- NCT05332704
- Locations
- 🇲🇩
Arensia Exploratory Medicine Phase 1 Unit, Chisinau, Moldova, Republic of
🇷🇴Arensia Exploratory Medicine, Bucharest, Romania
🇬🇧Medicines Evaluation Unit, Manchester, United Kingdom
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 626
- Registration Number
- NCT05144854
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
🇯🇵IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 217
- Registration Number
- NCT05079282
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸University of California Irvine Medical Center - Chao Family Comprehensive Cancer Center, Orange, California, United States
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
- Conditions
- Primary CNS LymphomaRefractory Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 112
- Registration Number
- NCT04947319
- Locations
- 🇺🇸
University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
🇺🇸Mayo Clinic- Phoenix, Phoenix, Arizona, United States
🇺🇸City of Hope Comprehensive Breast Cancer Center, Duarte, California, United States
A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 155
- Registration Number
- NCT04657497
- Locations
- 🇯🇵
Tokyo Clinical Site 9, Bunkyo-ku, Tokyo, Japan
🇯🇵Kanagawa Clinical Site 3, Kawasaki, Kanagawa, Japan
🇯🇵Saitama Clinical Site 2, Kumagaya, Saitama, Japan
A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of ONO-2808-01 in Healthy Participants
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 94
- Registration Number
- NCT04578028
- Locations
- 🇬🇧
Parexel International Early Phase Clinical Unit (EPCU), London, United Kingdom
ONO-4538 Phase II Rollover Study (ONO-4538-98)
- Conditions
- Pan-tumor
- Interventions
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 59
- Registration Number
- NCT04566380
- Locations
- 🇯🇵
Kanagawa Clinical Site1, Yokohama, Kanagawa, Japan
🇯🇵Tokyo Clinical Site3, Bunkyo-ku, Tokyo, Japan
🇯🇵Chiba Clinical Site2, Chiba, Japan